lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure
Oslo Univ Hosp, Norway;Oslo University Hospital Rikshospitalet, Norway.
Oslo Univ Hosp, Norway;Univ Oslo, Norway.
Oslo Univ Hosp, Norway.
Oslo University Hospital Rikshospitalet, Norway.
Show others and affiliations
2021 (English)In: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 12, article id 800978Article in journal (Refereed) Published
Abstract [en]

Objective: Dysregulation of the complement system has been described in patients with heart failure (HF). However, data on the alternative pathway are scarce and it is unknown if levels of factor B (FB) and the C3 convertase C3bBbP are elevated in these patients. We hypothesized that plasma levels of FB and C3bBbP would be associated with disease severity and survival in patients with HF. Methods: We analyzed plasma levels of FB, C3bBbP, and terminal C5b-9 complement complex (TCC) in 343 HF patients and 27 healthy controls. Results: Compared with controls, patients with HF had elevated levels of circulating FB (1.6-fold, p < 0.001) and C3bBbP (1.3-fold, p < 0.001). In contrast, TCC, reflecting the terminal pathway, was not significantly increased (p = 0.15 vs controls). FB was associated with NT-proBNP, troponin, eGFR, and i.e., C-reactive protein. FB, C3bBbP and TCC were not associated with mortality in HF during a mean follow up of 4.3 years. Conclusion: Our findings suggest that in patients with HF, the alternative pathway is activated. However, this is not accompanied by activation of the terminal pathway.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2021. Vol. 12, article id 800978
Keywords [en]
heart failure, complement, alternative pathway, complement Factor B, C3bBbP, terminal complement complex
National Category
Cardiac and Cardiovascular Systems Immunology in the medical area
Research subject
Natural Science, Medicine; Biomedical Sciences, Immunology
Identifiers
URN: urn:nbn:se:lnu:diva-109893DOI: 10.3389/fimmu.2021.800978ISI: 000743299500001PubMedID: 35003128Scopus ID: 2-s2.0-85122446637Local ID: 2021OAI: oai:DiVA.org:lnu-109893DiVA, id: diva2:1632805
Available from: 2022-01-27 Created: 2022-01-27 Last updated: 2024-01-17Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nilsson, Per H.

Search in DiVA

By author/editor
Nilsson, Per H.
By organisation
Department of Chemistry and Biomedical SciencesAdvanced Materials
In the same journal
Frontiers in Immunology
Cardiac and Cardiovascular SystemsImmunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 71 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf